natgillin/translations-raw huggingface dataset:
Det primære effektmål var fedtabsorptionskoefficienten over 72 timer (CFA-72t), der blev beregnet i slutningen af hver behandlingsperiode på basis af afføringsprøver indsamlet i løbet af de sidste tre dage i perioden.
The primary efficacy endpoint was the coefficient of fat absorption over 72 hours (CFA-72h) which was calculated at the end of each treatment period, from the stools collected during the last 3 days of each treatment period.
Det understøttende studie EUR-1008-M, der blev gennemført i USA, er et randomiseret, dobbeltblindt, placebokontrolleret cross-over-studie med 34 patienter i alderen 7-23 år med eksokrin pancreasinsufficiens forårsaget af cystisk fibrose.
The supportive EUR-1008-M, conducted in the US, was a randomized, double-blind, placebo-controlled, crossover study of 34 patients, ages 7 to 23 years, with EPI due to CF.
De fleste af disse bivirkninger var lette til moderate i sværhedsgrad i de kliniske studier.
In clinical trials, most of them were mild to moderate in severity.
Den kortsigtede virkning af og sikkerhed ved Enzepi blev bedømt i kliniske studier hos pædiatriske patienter i alderen 1 til 17 år med eksokrin pancreasinsufficiens forårsaget af cystisk fibrose.
The short-term efficacy and safety of Enzepi were assessed in clinical studies in paediatric patients, ages 1 to 17 years, with EPI due to CF.
På dag 2 kunne dosen af det tildelte studielægemiddel så ændres (titreres op eller ned) for at stabilisere symptomerne på eksokrin pancreasinsufficiens.
Then, starting on the second day, the dose of assigned treatment could be changed (titrated up and/or titrated down) to stabilize the symptoms of EPI.
De mest relevante klasseeffekter ved pancreasenzym-præparater inkluderer fibroserende colonopati, hyperurikæmi/hyperurikosuri og anafylaktiske reaktioner.
The most relevant class effects of the pancreatic enzyme products include fibrosing colonopathy, hyperuricaemia/ hyperuricosuria and anaphylactic reactions.
Indehaver af markedsføringstilladelsen Allergan Pharmaceuticals International Limited Clonshaugh Industrial Estate Coolock
Marketing Authorisation Holder Allergan Pharmaceuticals International Limited Clonshaugh Industrial Estate Coolock
Det kan resultere i for tidlig frigivelse af enzymerne i mundhulen, irritation af slimhinderne og tab af enzymaktivitet.
This can result in early release of the enzymes in the oral cavity, irritation of the mucous membranes and may lead to loss of enzyme activity.
Lavt blodglucose Forhøjet blodglucose Vægttab
Blood glucose decreased Blood glucose increased Weight decreased Weight increased
Hvis du eller dit barn har problemer med at synke Enzepi-kapslerne, kan du forsigtigt åbne dem og blande indholdet (granulatet) med en lille smule syreholdig mad, f.eks. frugtmos (æble eller pære), yoghurt eller juice (appelsin, ananas eller æble).
If you or your child have trouble swallowing Enzepi capsules, open carefully the capsules and sprinkle the contents (granules) on a small amount of acidic food such as fruit puree (apple/ pear), yoghurt, or juice (orange/pineapple/apple).
Enzepi skal altid tages sammen med et hovedmåltid eller et mellemmåltid.
Enzepi should always be taken with a meal or snack.
Enzepi tilhører gruppen af pancreasenzym-præparater og har et defineret indhold af lipase, amylase og protease, udvundet af svinepancreas og renset ved en proces, der er designet til at inaktivere vira.
Enzepi belongs to the family of pancreatic enzyme products and contains a defined amount of lipase, amylase and protease that have been extracted from porcine pancreas and purified using a process designed to inactivate viruses.
Ikke desto mindre forventes der ingen bivirkninger hos det ammede barn, da den diegivende kvinde ikke forventes at blive systemisk eksponeret for pancreasenzymerne i Enzepi.
Nevertheless, undersirable effects on the breastfed newborn/infant are not anticipated since systemic exposure in breast-feeding women to the pancreatic enzymes present in Enzepi is not expected.
Giv straks derefter barnet noget mælk, modermælkserstatning eller modermælk for at sikre, at al granulatet synkes, og at intet er tilbage i munden.
Immediately give them milk, formula or breast-milk to drink to ensure the granules are completely swallowed and none remain in your child's mouth.
mindst 7.800 enheder*
not less than 7,800 units*
Din samlede daglige dosis må ikke overstige 2.500 lipase-enheder pr. kg legemsvægt pr. måltid (eller 10.000 lipase-enheder pr. kg legemsvægt pr. dag).
Your total daily dose should not exceed 2,500 lipase units per kg of body weight per meal (or 10,000 lipase units per kg of body weight per day).
Børn (over 4 år), unge og voksne (herunder ældre) Den anbefalede startdosis for børn over 4 år, unge (12-18 år) og voksne er 500 lipase-enheder/kg legemsvægt ved hvert måltid.
Children (over 4 years of age), adolescents and adults (including elderly) The recommended starting dose for children over 4 years of age, adolescents (12 to 18 years) and adults is 500 lipase units per kg of body weight per meal.
Den gennemsnitlige CFA-72t var 88 % ved Enzepi-behandling og 63 % ved placebo.
Mean CFA-72h was 88% with Enzepi treatment compared to 63% with placebo treatment.
Til spædbørn under 1 år er den anbefalede startdosis 5.000 lipase-enheder pr. måltid (typisk 120 ml mælk) (se afsnittet "Administration").
For infants below 1 year of age the recommended starting dose is 5,000 lipase units per meal (generally 120 ml of milk) (see section Method of administration).
Den højeste anbefalede samlede dosis er 2.500 lipase-enheder/kg legemsvægt pr. måltid (eller 10.000 lipase-enheder/kg legemsvægt pr. dag) eller 4.000 lipase-enheder/g fedt indtaget pr. dag.
The maximum recommended total dose is 2,500 lipase units/kg of body weight per meal (or 10,000 lipase units/kg of body weight per day), or 4,000 lipase units/g fat ingested per day.
Det primære effektmål var middelforskellen i fedtabsorptionskoefficient (CFA-72t) mellem Enzepi og placebo.
The primary efficacy endpoint was the mean difference in the coefficient of fat absorption (CFA-72h) between Enzepi and placebo treatment.
Pancreasenzym-substitutionsterapi ved eksokrin pancreasinsufficiens forårsaget af cystisk fibrose eller andre tilstande (f.eks. kronisk pancreatitis, efter pankreatektomi, pancreascancer).
Pancreatic enzyme replacement treatment in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer).
Det skal du vide, før du begynder at tage Enzepi
What you need to know before you take Enzepi
Statistik opsummering Gennemsnit (SD) Median (minimum-maksimal)
Median (minimum - maximum)
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver kapsel indeholder: lipase:
STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains: lipase:
Der er rapporteret om strikturer i ileum-caecum og tyktarm (fibroserende colonopati) hos patienter med cystisk fibrose, der fik høje doser af pancreatinpræparater.
Strictures of the ileo-caecum and large bowel (fibrosing colonopathy) have been reported in patients with cystic fibrosis taking high doses of pancreatin preparations.
Spædbørn (under 1 år)
Infants (below 1 year of age)
Administrationen skal følges op af amning eller modermælkserstatning for at sikre, at alt indholdet i kapslen indtages.
Administration should be followed by breast-milk or formula to ensure complete ingestion.
Den gennemsnitlige forskel i CFA-72t var 26 procentpoint højere med Enzepi-behandling (95 %-KI: 19; 32; p < 0,001).
The mean difference in CFA-72h was 26 percentage points greater with Enzepi treatment with a 95% Confidence Interval of (19, 32) and p<0.001.
Øvrige indholdsstoffer: o Kapselindhold: croscarmellosenatrium, hydrogeneret ricinusolie, vandfri kolloid silica, mikrokrystallinsk cellulose, magnesiumstearat, hypromellosephthalat, talcum, triethylcitrat.
- The other ingredients are: o Capsule content: croscarmellose sodium, hydrogenated castor oil, colloidal anhydrous silica, cellulose microcrystalline, magnesium stearate, hypromellose phthalate, talc, triethyl citrate.
Patienter, der ikke kan synke kapslerne hele, kan åbne kapslerne forsigtigt og blande indholdet (uden at knuse det) med små mængder sure, bløde madvarer med en pH på 5 eller derunder (f.eks. frugtmos (æble eller pære), yoghurt, juice (appelsin, ananas, æble)).
For patients who are unable to swallow capsules whole, the capsules may be carefully opened and the contents mixed (without crushing) with small amounts of acidic soft food of pH 5 or less (e.g., fruit puree [apple/ pear], yoghurt, juice [orange/pineapple/apple]).
Kapselindhold (enterogranulat) Croscarmellosenatrium Hydrogeneret ricinusolie Vandfri kolloid silica Mikrokrystallinsk cellulose Magnesiumstearat Hypromellosephthalat Talcum
Capsule content (gastro-resistant granules) Croscarmellose sodium Hydrogenated castor oil Colloidal anhydrous silica Microcrystalline cellulose Magnesium stearate
Der skal udvises forsigtighed ved ordinering af Enzepi til patienter med tidligere urinsyregigt, nyresvigt eller hyperurikæmi.
Caution must be exercised when prescribing Enzepi to patients with a history of gout, renal impairment, or hyperuricaemia.
4.4 og 4.9) og kun, hvis det ved fæces-fedtmålinger over 3 dage, der viser en væsentligt forbedret fedtabsorptionskoefficient, kan dokumenteres, at de er effektive.
Higher doses should be used with caution if warranted (see sections 4.4 and 4.9) and only if they are documented to be effective by 3day faecal fat measurements that indicate a significantly improved coefficient of fat absorption.
Baseret på deres farmakologi forårsager pancreasenzymer ingen farmakokinetiske eller farmakodynamiske interaktioner, da de ikke absorberes fra mave-tarm-kanalen.
Pancreatic enzyme medicinal products do not cause pharmacokinetic and pharmacodynamic interactions based on their pharmacology, as they are not absorbed from the gastrointestinal tract.
Tabel 1 Analyse af fedtabsorptionskoefficienten over 72 timer (CFA-72t) - Patienter, der
Table 1 Analysis of coefficient of fat absorption over 72 hours (CFA72h) - completers population (study : PR005)
Det bør overvejes at monitorere blodglucose hos patienter med risiko for unormale blodglucoseniveauer, da den glykæmiske kontrol kan blive påvirket af substitutionsbehandling med pancreasenzymer (se pkt.
Consideration should be given to blood glucose monitoring in patients at risk of abnormal blood glucose levels as glycaemic control may be affected by administration of pancreatic enzyme replacement therapy (see section 4.8).
Enzepi skal tages til et hovedmåltid eller mellemmåltid sammen med et glas vand eller juice.
Enzepi should be taken during meals or snacks, with a drink of water or juice.
Bland ikke kapsel-indholdet direkte i modermælkserstatning eller modermælk.
Do not sprinkle the capsule contents directly into the formula or breast-milk.
Enzepi viste både non-inferioritet og ækvivalens i forhold til komparatoren med hensyn til kontrolleret absorption af fedt (målt som CFA-72t) hos unge og voksne med eksokrin pancreasinsufficiens relateret til cystisk fibrose.
Thus, Enzepi demonstrated both non-inferiority and equivalence to the comparator in fat absorption control (measured as CFA-72h) in adolescents and adults with CF-associated EPI.
Der er ikke gennemført prækliniske undersøgelser af Enzepi, men da pancreasenzymer ikke optages fra mave-tarm-kanalen, forventes der ingen systemisk toksicitet efter oral administration af pancreaspulver.
However as pancreatic enzymes are not absorbed from the gastrointestinal tract, no systemic toxicity is expected following oral administration of pancreas powder.
CFA-72t blev bestemt på grundlag af en 72 timers afføringsindsamling i de 2 behandlinger, hvor både fedtudskillelse og fedtindtagelse blev målt.
The CFA-72h was determined by a 72-hour stool collection during both treatments, when both fat excretion and fat ingestion were measured.
Gentagne høje doser af lægemidler til erstatning af pancreas-enzymer kan også forårsage ardannelse eller fortykkelse af tarmvæggen, hvilket kan medføre blokering af tarmene (fibroserende colonopati).
Repeated high doses of pancreatic enzyme replacement medicines can also cause scarring or thickening of the bowel wall that can lead to blockage of the intestines, a condition called fibrosing colonopathy.
Det vides ikke, om Enzepi udskilles i mælken hos mennesker.
It is not known if Enzepi passes into your breast-milk.
Bland ikke Enzepi-granulatet med vand, mælk, modermælk, modermælkserstatning, aromatiseret mælk eller varm mad.
Do not mix the Enzepi granules with water, milk, breast-milk, formula feeds, flavoured milk or hot food.
Vær sikker på, at al medicinen og madblandingen synkes, og at der ikke er noget granulat tilbage i munden.
Make sure the medicine and food mixture is swallowed completely and that no granules are left in your or your child's mouth.
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter): ubehag i maven eller oppustethed luft i maven diarré hovedpine.
Common (may affect up to 1 in 10 people): abdominal discomfort or bloating flatulence/passing wind diarrhoea headache.
mindst 650 enheder*
not less than 650 units*
Enzepi-kapsler og deres indhold må ikke knuses eller tygges, da dette kan medføre irritation af slimhinden i munden.
Enzepi capsules or its contents should not be crushed or chewed as they can cause irritation inside your mouth.
o Prægeblæk: shellac, propylenglycol, indigotin (E132).
o Printing ink: shellac, propylene glycol, indigotine (E132).
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig.
Other medicines and Enzepi Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Hvis du blander Enzepi-granulatet med mad, skal du sørge for, at blandingen synkes lige efter, når du har tilberedt den, og derefter skal du drikke (eller give dit barn) et glas vand eller juice.
If you sprinkle the Enzepi granules on food, swallow the mixture or give it to your child straight after you have mixed it, followed by a drink of water or juice.
Studie PR-011 er et åbent cross-over-studie med 15 patienter i alderen 1-11 måneder med eksokrin pancreasinsufficiens forårsaget af cystisk fibrose.
Study PR-011 was an open-label crossover study in 15 patients, ages 1 to 11 months, with EPI due to CF.
Høje doser af pancreasenzymer er blevet forbundet med hyperurikosuri og hyperurikæmi og bør anvendes med forsigtighed hos patienter med tidligere urinsyregigt, nedsat nyrefunktion eller hyperurikæmi (se pkt.
High doses of pancreatic enzyme products have been associated with hyperuricosuria and hyperuricaemia, and should be used with caution in patients with a history of gout, renal impairment or hyperuricaemia (see section 4.4).
o Kapselskal:
o Capsule shell :
Så meget Enzepi skal du tage
How much Enzepi to take
EUR 1009-M er et åbent studie med en enkelt arm hos 19 patienter i alderen 1-6 år, som alle havde eksokrin pancreasinsufficiens forårsaget af cystisk fibrose.
EUR 1009-M was an open-label, single arm study in 19 patients, ages 1 to 6 years, with EPI due to CF.
Hos patienter med risiko for unormale blodglucoseniveauer kan den glykæmiske kontrol blive påvirket af substitutionsbehandling med pancreasenzymer (se pkt.
In patients at risk of abnormal blood glucose levels glycaemic control may be affected by administration of pancreatic enzyme replacement therapy (see section 4.4).
Den anbefalede startdosis til spædbørn under 1 år er 5.000 lipase-enheder pr. 120 ml modermælkserstatning eller modermælk.
The recommended starting dose for infants below 1 year of age is 5,000 lipase units per 120 ml of formula milk or breast-milk.
Hvis du får alvorlige mavesmerter, problemer med at komme af med afføringen (forstoppelse), kvalme eller opkastning, skal du fortælle det til lægen med det samme.
If you have severe stomach pain, trouble passing stools (constipation), nausea or vomiting, tell your doctor straightaway.
Pakningsstørrelser: beholder med 20, 50, 100 eller 200 hårde enterokapsler.
Pack size: one bottle of 20, 50, 100 or 200 gastro-resistant hard capsules.
Det skal sikres, at der ikke er noget Enzepi tilbage i munden.
Care should be taken to ensure that Enzepi is not retained in the mouth.
Kapselindholdet må ikke blandes med vand, mælk, modermælk, modermælkserstatning, aromatiseret mælk eller varm mad.
Do not mix with water, milk, breast-milk, formula, flavoured milk or hot food.
Abdominalt ubehag
Abdominal discomfort
Børn i alderen 4 år samt unge og voksne (herunder ældre) For børn i alderen 4 år og derover samt unge og voksne er den anbefalede startdosis 500 lipaseenheder/kg legemsvægt pr. måltid.
Paediatric population aged 4 years or older and adults (including elderly) For children aged 4 years or older, adolescents and adults the recommended starting dose is 500 lipase units/kg of body weight per meal.
Unormal fæces Misfarvning af fæces Hyppig afføring
Abnormal faeces Faeces discoloured Frequent bowel movements
Kronisk høje doser af pancreasenzymer er blevet forbundet med fibroserende colonopati og, som følge deraf, i nogle tilfælde colonstrikturer (se pkt.
Chronic high doses of pancreatic enzyme products have been associated with fibrosing colonopathy and as a result in some cases colonic strictures (see sections 4.2 and 4.4).
De alvorligste bivirkninger, der er set med andre lægemidler, der bruges til erstatning af pancreasenzymer, er anafylaktisk shock og blokering af tarmene (fibroserende colonopati).
The most important serious side effects seen with other pancreatic enzyme replacement medicines are ‘anaphylactic shock' and fibrosing colonopathy.
Data fra patienterne med cystisk fibrose og eksokrin pancreasinsufficiens kan ekstrapoleres til de andre årsager til eksokrin pancreasinsufficiens såsom kronisk pancreatitis, pancreascancer og efter pankreatektomi.
Data generated in the CF population with EPI can be extrapolated to the other causes of EPI such as chronic pancreatitis, post pancreatectomy or pancreatic cancer.
Endvidere for Enzepi 40.000 enheder enterogranulat Indigotin (E132)
Additionally for Enzepi 40,000 units gastro-resistant granules Indigotine (E132)
Nordmark Arzneimittel GmbH & Co.
Nordmark Arzneimittel GmbH & Co. KG Pinnauallee 4
- proteaseaktivitet:
- proteolytic activity:
Sørg for, at beholderen er tæt tillukket, og lad tørremidlet ligge i den for at beskytte mod fugt.
Keep the bottle tightly closed and the desiccant in the bottle in order to protect from moisture.
Enzymerne udvindes fra bugspytkirtlen hos svin.
The enzymes are taken from pig pancreas glands.
Enzepi-kapslerne eller deres indhold må ikke knuses eller tygges, og kapslerne eller deres indhold må ikke holdes i munden.
Enzepi capsules or the granules inside them should not be crushed or chewed and the capsules or the granules inside them should not be held in your or your child's mouth.
Efter anbrud: 6 måneder ved temperaturer under 25°C.
After first opening: 6 months when stored below 25°C.
- amylaseaktivitet: - proteaseaktivitet:
amylolytic activity: proteolytic activity:
Pancreasenzymer optages ikke fra mave-tarm-kanalen.
Pancreatic enzymes are not absorbed from the gastrointestinal tract.
Den anbefalede startdosis for børn i alderen 14 år er 1.000 lipase-enheder/kg legemsvægt ved hvert måltid.
The recommended starting dose for children between 1 and 4 years of age is 1,000 lipase units per kg of body weight with each meal.
HDPE-beholder med poser med tørremiddel, børnesikret lukke af polypropylen med indvendig beklædning og afrivelig forsegling.
HDPE bottle containing desiccant sachets, closed with a lined polypropylene childresistant closure and a peel-off sealing liner.
Kapselskal Hypromellose Carrageenan (E407) Kaliumchlorid Titandioxid (E171) Carnaubavoks Renset vand
Capsule shell Hypromellose Carrageenan (E407) Potassium chloride Titanium dioxide (E171) Carnauba wax Purified water
Bivirkningerne hos ældre med eksokrin pancreasinsufficiens var af samme hyppighed, type og sværhedsgrad som hos voksne.
Frequency, type and severity of adverse reactions were similar in elderly people with pancreatic exocrine insufficiency as compared to adults.
Kapslerne skal tages med et glas vand eller juice og synkes hele.
The capsules should be swallowed whole and take them with a drink of water or juice.
Allergiske reaktioner omfatter kløe, nældefeber og udslæt.
An allergic reaction could include itching, hives or rash.
- amylaseaktivitet:
- amylolytic activity:
Aktive stoffer: Det aktive stof er pancreas-pulver udvundet af pancreas (bugspytkirtler) fra svin.
What Enzepi contains - The active substance is pancreas powder of porcine origin.
25.000 enheder*
25,000 units*
Potentiel irritation af slimhinderne i munden
Potential for irritation to oral mucosa
Hvis du tidligere har haft urinsyregigt, nyresygdom eller et højt indhold af urinsyre i blodet (hyperurikæmi) eller urinen (hyperurikosuri)
Talk to your doctor or pharmacist before taking Enzepi if you have ever had gout, kidney disease, or high uric acid levels in your blood (hyperuricaemia) or in urine (hyperuricosuria), if you have abnormal blood glucose levels.
Bortskaf kapslen, hvis den ved et uheld bliver knust.
Dispose of any accidentally crushed capsule.
40.000 enheder*
40,000 units*
20 enterokapsler, hårde 50 enterokapsler, hårde 100 enterokapsler, hårde 200 enterokapsler, hårde
20 gastro-resistant hard capsules 50 gastro-resistant hard capsules 100 gastro-resistant hard capsules 200 gastro-resistant hard capsules
- lipaseaktivitet: :
lipolytic activity:
Sådan skal du tage Enzepi
How to take Enzepi
I sjældne tilfælde ses en alvorligere allergisk reaktion, der omfatter varmefølelse, svimmelhed, besvimelse og vejrtrækningsbesvær.
Rarely, a more serious allergic reaction may include a feeling of warmth, dizziness and fainting, trouble breathing; these are symptoms of a severe, potentially life-threatening condition called ‘anaphylactic shock'.
Træthed Utilpashed
Fatigue Malaise
EVENTUELLE ANDRE SÆRLIGE ADVARSLER Tørremidlet må ikke sluges.
OTHER SPECIAL WARNING(S), IF NECESSARY Do not swallow the desiccant.
Endvidere for Enzepi 25.000 enheder enterogranulat Gul jernoxid (E172)
Additionally for Enzepi 25,000 units gastro-resistant granules Yellow iron oxide (E172)
5.000 enheder*
5,000 units*
Enzepi 5.000 enheder, hårde enterokapsler Enzepi 10.000 enheder, hårde enterokapsler Enzepi 25.000 enheder, hårde enterokapsler Enzepi 40.000 enheder, hårde enterokapsler
Enzepi 5,000 units gastro-resistant hard capsules Enzepi 10,000 units gastro-resistant hard capsules Enzepi 25,000 units gastro-resistant hard capsules Enzepi 40,000 units gastro-resistant hard capsules
Virkningen af Enzepi er blevet undersøgt hos 130 patienter med eksokrin pancreasinsufficiens associeret med cystis fibrose i et studie med aktiv komparator og i et placebokontrolleret studie.
The efficacy of Enzepi has been evaluated in one active-comparator study and one placebo-controlled study conducted in 130 patients with EPI (exocrine pancreatic insufficiency) associated with CF.
I den første behandlingsperiode fik patienterne enten Enzepi eller komparator i 28 dage efterfulgt af overkrydsning til den anden behandling i endnu 28 dage.
28 days, followed by a cross-over to the alternate treatment for a second 28 day period.
Børn i alderen fra 1 til under 4 år
Children (between 1 and 4 years of age)
Enzepi indeholder en blanding af naturlige fordøjelsesenzymer til fordøjelse af maden, herunder lipase til fordøjelse af fedt, protease til fordøjelse af protein og amylase til fordøjelse af kulhydrater.
These include lipases for digesting fat, proteases for digesting protein and amylases for digestions carbohydrates.
Trafik- og arbejdssikkerhed Enzepi påvirker ikke evnen til at færdes sikkert i trafikken eller betjene maskiner.
Driving and using machines Enzepi does not affect your ability to drive or use tools or machines.
Hvis du blander Enzepi-granulatet med mad, skal du give dit barn blandingen med det samme.
If you sprinkle the Enzepi granules on food, give the medicine and food mixture to your child right away and do not store Enzepi that is sprinkled on food.